EP2742135

IONIS PHARMACEUTICALS, INC.
Application Number
EP12748812A
Filing Date
Aug 8, 2012
Status
Patent Maintained As Amended
May 8, 2020
Grant Date
Jun 10, 2020
External Links
Slate, Register

Biblio Summary

The patent EP2742135B2 was granted on Jun 10, 2020 by Ionis Pharmaceuticals, Inc. The patent is currently Patent Maintained As Amended.

The table below shows 1 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ROCHE INNOVATION CENTER COPENHAGEN A/SFeb 2, 2018WITHDRAWN

The table below shows the patents of Ionis Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3400947Modulation Of Apolipoprotein C-Iii (Apociii) Expression In Lipoprotein Lipase Deficient (Lpld) PopulationsAug 23, 20231
EP2906696Methods For Modulating C9Orf72 ExpressionDec 14, 20222
EP3461895Modulation Of Ube3A-Ats ExpressionJul 1, 20201